SENATE BILL 306
K1 5lr0818
By: Senator Beidle
Introduced and read first time: January 13, 2025
Assigned to: Finance
Committee Report: Favorable with amendments
Senate action: Adopted
Read second time: February 22, 2025
CHAPTER ______
1 AN ACT concerning
2 Workers’ Compensation – Prescription Drug and Pharmaceutical Services –
3 Reimbursements
4 FOR the purpose of requiring the State Workers’ Compensation Commission to regulate
5 fees and other charges for the reimbursement of prescription drugs and
6 pharmaceutical services under certain circumstances; limiting reimbursements to a
7 certain cost index or indexes; requiring the Maryland Prescription Drug Affordability
8 Board to conduct a certain study; and generally relating to reimbursement for
9 prescription drugs and pharmaceutical services under workers’ compensation law.
10 BY repealing and reenacting, with amendments,
11 Article – Labor and Employment
12 Section 9–663
13 Annotated Code of Maryland
14 (2016 Replacement Volume and 2024 Supplement)
15 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
16 That the Laws of Maryland read as follows:
17 Article – Labor and Employment
18 9–663.
19 (a) (1) The Commission shall adopt regulations setting standards for the
20 assessment of fines under § 9–664 of this Part IX of this subtitle.
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *sb0306*

2 SENATE BILL 306
1 (2) The Commission may adopt regulations about:
2 (i) the provision of medicine and medical, nursing, and hospital
3 services to a covered employee;
4 (ii) payment for the medicine and services; and
5 (iii) the exercise by the Chairman of the Commission of the powers
6 granted under § 9–662 of this subtitle.
7 (b) (1) The Commission may regulate fees and other charges for medical
8 services or treatment under this subtitle.
9 (2) (I) THE NOT LATER THAN SEPTEMBER 1, 2026, THE
10 COMMISSION SHALL REGULATE FEES AND OTHER CHARGES FOR THE
11 REIMBURSEMENT OF PRESCRIPTION DRUGS AND PHARMACEUTICAL SERVICES
12 UNDER THIS SUBTITLE PROVIDED BY A PERSON WHO HOLDS A PHARMACY PERMIT
13 UNDER TITLE 12, SUBTITLE 4 OF THE HEALTH OCCUPATIONS ARTICLE.
14 (II) REIMBURSEMENT UNDER SUBPARAGRAPH (I) OF THIS
15 PARAGRAPH SHALL BE LIMITED TO AN INDEX OR INDEXES BASED ON ACQUISITION
16 COST, CALCULATED ON A PER UNIT BASIS, AS OF THE DATE OF DISPENSING AND MAY
17 INCLUDE:
18 1. REASONABLE DISPENSING FEES; AND
19 2. ANY OTHER PERCENTAGE INCREASE OR DECREASE
20 DETERMINED BY THE COMMISSION.
21 (III) THIS PARAGRAPH DOES NOT PROHIBIT AN INSURANCE
22 CARRIER OR EMPLOYER FROM CONTRACTING WITH A PHARMACY BENEFITS
23 MANAGER, A NETWORK OF PHARMACIES, OR DISPENSING PROVIDERS:
24 1. FOR REIMBURSEMENT RATES DIFFERENT THAN
25 THOSE ESTABLISHED BY THE COMMISSION; OR
26 2. TO USE A PRICING INDEX OR INDEXES DIFFERENT
27 THAN THOSE SELECTED BY THE COMMISSION.
28 (3) Each fee or other charge for medical service or treatment under this
29 subtitle is limited to the amount that prevails in the same community for similar treatment
30 of an injured individual with a standard of living that is comparable to that of the covered
31 employee.

SENATE BILL 306 3
1 [(3)] (4) At least once every 2 years, the Commission shall:
2 (i) review its guide of medical and surgical fees for completeness and
3 reasonableness; and
4 (ii) make appropriate revisions to the guide of medical and surgical
5 fees.
6 SECTION 2. AND BE IT FURTHER ENACTED, That:
7 (a) The Maryland Prescription Drug Affordability Board:
8 (1) shall conduct a study on prescription drug affordability challenges
9 related to workers’ compensation claims that includes:
10 (i) an overview of prescription drug prescribing and billing practices
11 and trends that are specialized to the workers’ compensation market;
12 (ii) research into specific prescribing, billing, and dispensing
13 practices, including:
14 1. prescribing high cost formulations and compounded
15 formulations of commonly available drugs;
16 2. billing and dispensing from entities that do not bill or
17 provide services in the health insurance market; and
18 3. billing practices using billing codes without standardized
19 pricing metrics; and
20 (iii) making recommendations, if applicable, for policies to address
21 identified affordability challenges; and
22 (2) may require, subject to applicable federal and State laws, entities that
23 pay, prescribe, bill, and dispense prescription drugs under workers’ compensation claims
24 to report information to the Board as necessary to complete the study.
25 (b) On or before March 1, 2026, the Prescription Drug Affordability Board shall
26 report its findings and any recommendations to the Senate Finance Committee and the
27 House Economic Matters Committee, in accordance with § 2–1257 of the State Government
28 Article.
29 SECTION 2. 3. AND BE IT FURTHER ENACTED, That this Act shall take effect
30 October July 1, 2025.

[DELETED: :CA      5     A W R F f a o c f t r o p d a p c B t c a c s a g r t r f p B  A S  A  (  S T A 9  ( ( T C s a r s s f t a]
[DELETED:  S    ( T    ( t p o m a m n a h s    ( p    ( t g  ( ( T C m r f a o c f m s   ( ) TNS1,2H O L T E   T S R F A O C F T O P D A P S I  U   E C R1,S4HOA    ) R(IE U S I O TT S       .S       O P I O D O   ()IH P D N P A I  O E F C W A P BR S S,       R R D T ON        U A P I O I D O      E s o e]
[DELETED: S 3   () A](    ( r r    ( m f  S  ( T   ( s c a s o p d a c r    ( a a    ( r i s p b a d p     1 p h c f a c f     2 b a d f e t d n b o p     3 b p    ( m i   ( m p t  ( O r H A  S O]